Scarica l'app Stockscreener
165.35
0.20%
-0.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$165.68
Aprire:
$164.57
Volume 24 ore:
1.12M
Relative Volume:
0.72
Capitalizzazione di mercato:
$11.45B
Reddito:
$2.90B
Utile/perdita netta:
$302.80M
Rapporto P/E:
38.48
EPS:
4.2965
Flusso di cassa netto:
$387.80M
1 W Prestazione:
+1.28%
1M Prestazione:
+8.60%
6M Prestazione:
-35.36%
1 anno Prestazione:
-42.67%
Intervallo 1D:
$162.43
$168.36
Intervallo di 1 settimana:
$161.62
$172.91
Portata 52W:
$138.79
$354.88
Insulet Corp Stock (PODD) Company Profile
Nome
Insulet Corp
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
165.35 | 11.43B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | Downgrade | Citigroup | Buy → Neutral |
| 2026-01-27 | Ripresa | TD Cowen | Hold |
| 2026-01-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Iniziato | Evercore ISI | Outperform |
| 2025-11-19 | Aggiornamento | UBS | Neutral → Buy |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corp Borsa (PODD) Ultime notizie
PODD SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Insulet Corporation Investors - GlobeNewswire Inc.
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Corp (PODD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insulet Corp (PODD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Insulet Market Sentiment - Benzinga España
Insulet Corp (PODD) Income Statement - TradingKey
PODD|Insulet Corp|Price:164.940|Chg%:+1.680 - TradingKey
Insulet Corp (PODD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Insulet Corp (PODD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD - GlobeNewswire Inc.
Insulet Corp Shs Unsponsored Brazilian Depositary Receipt Repr 0.03333333 Sh - TradingView
Insulet Corp (PODD) Cash Flow - TradingKey
Insulet Corp (PODD) Shares Surge 3.1% -- What GF Score of 81 Tel - GuruFocus
Insulet examines mental health toll of diabetes in partnership with meditation app Calm - Medical Marketing and Media
Insulet Corp (PODD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit - PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain OfficersPODD - PR Newswire
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Insulet Corporation (PODD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insulet's Q2 2026 Earnings: What to Expect - Yahoo Finance
Insulet Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Insulet Corporation Class Action Reminder – Robbins LLP - GlobeNewswire
Insulet stock trades steady as Omnipod growth supports long term diabetes opportunity - Ad-hoc-news.de
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Planet Fitness, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
PODD EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - marketscreener.com
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation - GlobeNewswire
Lost Money on Insulet Corporation (PODD)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - GlobeNewswire
PODD SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - marketscreener.com
Robbins LLP Urges PODD Stockholders to Contact the Firm for Information About the Class Action Against Insulet Corporation - TMX Newsfile
PODD DEADLINE: The Gross Law Firm Reminds Insulet - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Insulet stock trades near recent lows as Omnipod margins tighten after GLP-1 demand shift - Ad Hoc News
Insulet Corp (PODD) Stock Up 3.2% and Still Undervalued -- GF Sc - GuruFocus
Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Insulet Corp (NASDAQ:PODD): A Quality Affordable Growth Stock With Strong Earnings Momentum - ChartMill
Lila Moss narrates a new sleep story for the diabetes community - Stock Titan
INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Insulet Investors of - The National Law Review
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
PODD Court News: Insulet Class Action Lawsuit Alleges Securities Fraud on behalf of Investors with Losses - PR Newswire
Insulet Corporation (PODD) Fell Along with Broad Medtech Sector - Yahoo Finance
Here's How Much You'd Have If You Invested $1000 in Insulet a Decade Ago - Yahoo Finance
Lobbying Update: $60,000 of INSULET CORPORATION lobbying was just disclosed - Quiver Quantitative
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Insulet - GlobeNewswire
PODD Shareholder Alert: Insulet Corporation Securities - GlobeNewswire
Stifel cuts Insulet stock price target on valuation, keeps buy rating - Investing.com
Insulet stock reflects steady diabetes tech demand as investors watch U.S. growth - AD HOC NEWS
Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47% - Yahoo Finance
Insulet (PODD) Launches Omnipod 5 In Spain, Is The Stock Cheap? - Yahoo Finance
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 31, 2026 in Insulet Corporation LawsuitPODD - Morningstar
PODD Shareholder Alert: Insulet Corporation Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - Business Wire
Insulet Corp Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insulet Corp Azioni (PODD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BORIO LUCIANA | Director |
Jun 03 '26 |
Sale |
143.27 |
418 |
59,887 |
4,329 |
| WEATHERMAN ELIZABETH H | Director |
Jun 03 '26 |
Buy |
144.20 |
3,450 |
497,490 |
10,352 |
1.04%
11.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):